Skip to main navigation Skip to search Skip to main content

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Research output: Contribution to journal › Article › peer-review

2026   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science